Lisa Graver serves as the CEO for Alvogen and its affiliate Almatica.  She brings over 20 years of distinguished experience in the pharmaceutical industry to her role. Her profound knowledge in patent law and regulatory strategy has been integral to Alvogen’s success. Under Lisa’s leadership, Almatica is actively pursuing the expansion of its US product portfolio through development and acquisition of products.

Lisa holds her Juris Doctorate from Case Western University School of Law and an Honors Bachelor of Science degree from Lakehead University.